Clinical trials: Carcinoma, Colorectal
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Imaging of Solid Gastrointestinal Tumors
A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
This study is a first-in-human (FIH), single-dose, open-label, phase 1 study designed to assess the safety, pharmacokinetics (PK), distribution, and radiation dosimetry of [68Ga]MLN6907 after a single intravenous (IV)…
- Trial name
- NCT02056015
- Testing
- [68Ga]MLN6907
- Where
- 2 sites in United States, Mexico
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Breast Cancer, Lung Cancer
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03662204
- Testing
- Blood Sample Collection
- Where
- 119 sites in United States
- Volunteers
- 5,133 people
- Sponsor
- Exact Sciences Corporation
Cancer, Colon Cancer
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Metastatic Cancer
- Trial name
- NCT00418938
- Testing
- Panitumumab, Bevacizumab, Leucovorin
- Volunteers
- 266 people
- Sponsor
- Amgen
Colorectal Surgery, Colorectal Cancer
Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
The purpose of this study is to evaluate the Colorectal Balloon Tube (hereinafter referred to as COLO-BT™) device, a single use, temporary intraluminal bypass device, intended to reduce contact of fecal content with an…
- Conditions
- Colorectal Surgery, Colorectal Cancer, Rectal/Anal, Ileostomy - Stoma
- Trial name
- COLO-BT (NCT05826743)
- Testing
- COLO BT™, Stoma Creation
- Where
- 3 sites in United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- JSR Medical Co., Ltd.
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
Colorectal Cancer
Evaluation of CG-100 Intraluminal Bypass Device
Evaluation of CG-100 Intraluminal Bypass device
- Trial name
- NCT05632744
- Testing
- CG-100 Intraluminal Bypass Device
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Colospan Ltd.
Colorectal Cancer
A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
This expanded access study will assess the efficacy and safety of intravenous (IV) bevacizumab in combination with chemotherapy regimens as first-line treatment of metastatic cancer of the colon or rectum.
- Trial name
- NCT02582970
- Testing
- 5-Fluorouracil, Bevacizumab, Irinotecan
- Where
- 8 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Gastrointestinal Cancer, Gastrointestinal Neoplasms
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms
- Trial name
- NCT03597581
- Testing
- ompenaclid, FOLFIRI, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 89 people
- Sponsor
- Inspirna, Inc.
Refractory Metastatic Colorectal Cancer, Solid Tumor
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients.
- Conditions
- Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient
- Trial name
- NCT05205330
- Testing
- CR6086, AGEN2034
- Where
- 3 sites in Italy
- Volunteers
- 107 people
- Sponsor
- Rottapharm Biotech
Colorectal Cancer Metastatic
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated.
- Trial name
- NCT06634875
- Testing
- isunakinra
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Buzzard Pharmaceuticals
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Renal Cell Carcinoma, Non-small Cell Lung Cancer
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing…
- Conditions
- Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05769959
- Testing
- RO7515629, tocilizumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer.
- Trial name
- NCT00047762
- Testing
- Erlotinib (aka Tarceva or OSI-774), Bevacizumab (aka Avastin or Rhu MAb VEGF)
- Where
- 3 sites in United States
- Sponsor
- Genentech, Inc.
Colorectal Cancer
Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer
In this study, patients will receive either pemetrexed plus irinotecan or 5-fluorouracil (5-FU), leucovorin, and irinotecan. The purposes of this study are to determine: How pemetrexed plus irinotecan compares with 5-FU…
- Trial name
- NCT00079872
- Testing
- Pemetrexed
- Where
- 6 sites in Australia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients
This study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments.
- Trial name
- NCT07314294
- Testing
- EMB-01 1600 mg administered once weekly throughout the study, EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Colorectal Neoplasms
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC)…
- Trial name
- NCT04515394
- Testing
- Tepotinib, Cetuximab
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Neoplasms, Advanced Solid Tumors
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74699157 in participants with advanced solid tumors harboring a kirsten rat sarcoma virus homolog (KRAS)…
- Conditions
- Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT04006301
- Testing
- JNJ-74699157
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Solid Tumor, Non-small Cell Lung Cancer
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05369312
- Testing
- BPI-442096
- Where
- 5 sites in China
- Volunteers
- 230 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.